Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2 STUDY OF IBRUTINIB COMBINATION THERAPY IN TRANSPLANT INELIGIBLE INDIVIDUALS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Intervention/treatment:
IBRUTINIB
Medical condition:
CENTRAL NERVOUS SYSTEM LYMPHOMA
Protocol code:
IND.244
Control number:
274361
Status:
Recruiting
Approved:
May 11, 2023
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05998642
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Annette Hay
Role
CONTACT
Phone:
613-533-6430
Sponsor
CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Locations

Alberta

Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
Recruiting
Name
Robert Puckrin
Role
CONTACT
Phone:
403 944-5222

British Columbia

BCCA - Vancouver
Vancouver, British Columbia, V5Z 4E6
Recruiting
Name
Diego Villa Restrepo
Role
CONTACT
Phone:
604 877-6000
Extension 2740

Ontario

Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2
Recruiting
Name
Graeme Fraser
Role
CONTACT
Phone:
905 575-7820
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6
Recruiting
Name
David A. MacDonald
Role
CONTACT
University Health Network
Toronto, Ontario, M5G 2M9
Recruiting
Name
Anca Prica
Role
CONTACT
Phone:
416 946-4501
Extension 2249

Quebec

CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)
Québec, Quebec, G1J 1Z4
Recruiting
Name
Jean-Francois Larouche
Role
CONTACT
The Research Institute of the McGill University
Montreal, Quebec, H4A 3J1
Recruiting
Name
Kelly Davison
Role
CONTACT
Phone:
514 934-1934
Extension 31558

Saskatchewan

Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Recruiting
Name
Abdulhakim Eswedi
Role
CONTACT
Phone:
306 766-2691
Did you find what you were looking for?